| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tnfrsf10b |
| Uniprot No | O14763 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-210aa |
| 氨基酸序列 | ALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDY STHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMC RKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPG TPASPCS |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Tnfrsf10b(DR5)重组蛋白的3篇参考文献概述：
1. **"Crystal structure of the TRAIL-DR5 complex reveals mechanisms of receptor activation"**
- **作者**: Hymowitz SG, et al.
- **摘要**: 通过X射线晶体学解析了TRAIL与重组DR5胞外结构域的复合物结构，揭示了受体激活的分子机制，为基于DR5的靶向药物设计提供结构基础。
2. **"Recombinant soluble DR5 induces apoptosis and synergizes with chemotherapy in preclinical cancer models"**
- **作者**: Chuntharapai A, et al.
- **摘要**: 研究报道了一种重组可溶性DR5蛋白的制备方法，证明其可诱导多种癌细胞凋亡，并与化疗药物协同增强抗肿瘤效果。
3. **"Production and functional characterization of a recombinant death receptor 5 agonist"**
- **作者**: Kelley RF, et al.
- **摘要**: 描述了重组DR5激动剂蛋白的表达、纯化及功能验证，显示其通过激活caspase通路选择性杀伤肿瘤细胞，具有潜在治疗应用价值。
这些文献涵盖了DR5重组蛋白的结构解析、功能验证及治疗应用方向的研究。
TNFRSF10B, also known as TRAIL-R2 or DR5 (Death Receptor 5), is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It plays a critical role in apoptosis regulation by binding to its ligand, TNF-related apoptosis-inducing ligand (TRAIL/Apo2L), which triggers extrinsic apoptotic signaling pathways. Structurally, TNFRSF10B contains cysteine-rich extracellular domains for ligand interaction, a transmembrane region, and a cytoplasmic death domain essential for recruiting adaptor proteins like FADD to activate caspases.
Recombinant TNFRSF10B protein is typically produced in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to generate soluble forms of the receptor. These engineered variants often lack the transmembrane domain and may include tags (e.g., Fc or His tags) for purification and detection. Recombinant TNFRSF10B retains ligand-binding capability, enabling its use in studying TRAIL-mediated apoptosis mechanisms. It competes with endogenous receptors for TRAIL binding, modulating apoptotic signals in cancer cells or immune cells.
Research applications include investigating TRAIL/TNFRSF10B interactions in cancer biology, autoimmune disorders, and neurodegenerative diseases. In therapeutics, recombinant TNFRSF10B is explored as a decoy receptor to neutralize TRAIL in conditions involving excessive apoptosis or as an agonist to sensitize TRAIL-resistant tumors. Its role as a biomarker for disease progression or treatment response is also under study. Current challenges involve optimizing receptor stability and delivery strategies for clinical translation.
×
